SWHR Recommends ICER Delay Report on Endometriosis Treatments

In comments to the Institute for Clinical and Economic Review (ICER), SWHR recommended the organization delay finalizing its draft evidence report assessing new endometriosis therapies until they have been more thoroughly studied by Food and Drug Administration (FDA). Examining the draft report in detail, SWHR noted areas where ICER’s methodology, modeling techniques, and key inputs could be refined.

SWHR pointed out the limitations within the draft evidence report that make a clear assessment of the new therapies difficult. For example, ICER’s analysis compared the cost-effectiveness of elagolix to no treatment (i.e., placebo) and was unable to compare to other treatments due to lack of data. Delaying the report until more comprehensive studies are completed would allow ICER to produce a more thorough assessment comparing the cost-effectiveness of treatments. SWHR also made recommendations to ICER for improving or refining future analyses.

Learn more about endometriosis through the work of SWHR’s Interdisciplinary Network on Endometriosis and Fibroids.

In comments to the Institute for Clinical and Economic Review (ICER), SWHR recommended the organization delay finalizing its draft evidence report assessing new endometriosis therapies until they have been more thoroughly studied by Food and Drug Administration (FDA). Examining the draft report in detail, SWHR noted areas where ICER’s methodology, modeling techniques, and key inputs could be refined.

SWHR pointed out the limitations within the draft evidence report that make a clear assessment of the new therapies difficult. For example, ICER’s analysis compared the cost-effectiveness of elagolix to no treatment (i.e., placebo) and was unable to compare to other treatments due to lack of data. Delaying the report until more comprehensive studies are completed would allow ICER to produce a more thorough assessment comparing the cost-effectiveness of treatments. SWHR also made recommendations to ICER for improving or refining future analyses.

Learn more about endometriosis through the work of SWHR’s Interdisciplinary Network on Endometriosis and Fibroids.

SWHR’s ICER Engagement

Blog Post
SWHR Develops Principles to Ensure Health Care Value Assessments Work for Women
When a new health care innovation comes to market, how do patients, health care providers, and health care payers determine its value?
Policy Engagement
SWHR Recommendations on ICER’s 2020 Value Assessment Framework
SWHR provided recommendations to the Institute for Clinical and Economic Review (ICER) on proposed changes to its 2020 value assessment framework to ensure it supports optimal health outcomes for women.
Policy Engagement
SWHR’s Health Care Value Assessment Principles
SWHR conceived a set of principles to ensure health care value frameworks and assessments reflect factors relevant to women and their health.
Policy Engagement
SWHR Provides Input on ICER Value Assessment Framework
SWHR provided input to the Institute for Clinical and Economic Review (ICER) on the 2020 update to its value assessment framework.
Blog Post
Determining the Value of New Therapies: ICER Explores the Role of Real-World Evidence
Women won’t benefit from new therapies unless they can access them, and patient access to new innovations is based, in part, on value assessment.
Policy Engagement
SWHR Input on ICER Migraine Therapies Draft Report
SWHR commented on ICER's migraine therapies draft report, regarding the effectiveness and value of calcitonin gene-related peptide (CGRP) inhibitors.
Policy Engagement
SWHR Urges ICER to Use Progressive Modeling to Assess Endometriosis Treatments
On February 1, 2018, SWHR submitted comments to the Institute for Clinical and Economic Review (ICER) before its assessment of the comparative clinical effectiveness of new treatments for endometriosis.
Policy Engagement
SWHR Urges ICER to Consider Disease Burden When Assessing Migraine Drugs
SWHR urged the Institute for Clinical and Economic Review (ICER) to incorporate the significant burden of migraine into its assessment of the effectiveness and value of drugs for migraine.